Objective: Estrogen (E 2 ) has an inhibitory effect on food intake by acting centrally in the hypothalamus, although it is not clear which hypothalamic neurons are involved in this process. Earlier studies from our lab and others have implicated neuropeptide Y (NPY) as an important central anorexigenic target of E 2 . This study was designed to investigate whether E 2 can directly regulate NPY secretion and examine the cellular mechanisms and receptors responsible for this anorexigenic action of E 2 . Design: Clonal, murine, hypothalamic neuronal cell models, mHypoE-42 and mHypoA-2/12, were investigated for NPY secretory responses to 17b-estradiol (E 2 ) in the presence or absence of pharmacological inhibitors directed against the phosphatidylinositol-3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and AMP-activated kinase (AMPK) pathways or to estrogen receptor (ER) specific agonists/antagonists. Measurements: The presence of hypothalamic markers and characterization of neuronal cell lines was completed with polymerase chain reaction. NPY levels were measured using an enzyme immunoassay (EIA). The expression of ER-a and caveolin-1 was analyzed using immunocytochemistry. Results: E 2 significantly decreased NPY secretion in both the mHypoE-42 and mHypoA-2/12 neurons. The E 2 -mediated repression of NPY secretion in the mHypoE-42 and mHypoA-2/12 neurons required ER-a, but not ER-b, as shown by studies using an ER-specific agonist/antagonists. Additionally, using immunocytochemistry we detected colocalization of ER-a and the membrane-associated signaling protein caveolin-1. Importantly, using E 2 -conjugated bovine serum albumin (E 2 -BSA) and ER antagonists, we were able to show that the E 2 -mediated decrease in NPY secretion occurred through membrane-bound ER-a. Finally, using a combination of pharmacological inhibitors, we found that inhibition of the PI3K or AMPK pathway blocked the E 2 -mediated decrease in NPY secretion. Conclusion: These findings indicate that the central anorexigenic action of E 2 occurs at least partially through hypothalamic NPY-synthesizing neurons. This regulation of NPY secretion occurs through rapid signaling mechanisms through membrane bound ER-a.
Introduction
Estrogen (E 2 ) withdrawal observed in postmenopausal women results in increased weight gain, visceral obesity and increased risk of diabetes.
1,2 E 2 replacement therapy can normalize these abnormalities by reducing food intake and increasing metabolic expenditure. 1, 2 This anorexigenic role of E 2 has also been shown in rodent studies. [3] [4] [5] Ovariectomized rats display increase in food intake and adipose tissue deposition, which can be readily reversed with the re-introduction of E 2 . 6 E 2 is thought to regulate energy homeostasis through two pathways: an anorexigenic action through the central nervous system and a direct action on tissue metabolism. 7 The central action of E 2 is hypothesized to occur through the regulation of multiple orexigenic and anorexigenic neuropeptides implicated in feeding behavior. [8] [9] [10] A large body of evidence suggests that neuropeptide Y (NPY) is involved with the E 2 -mediated decrease in feeding behavior. 8, 10, 11 NPY is a potent orexigenic peptide, as the central administration of NPY stimulates feeding and repeated doses results in an increase in body weight. 12, 13 Intracerebroventricular administration of NPY, induce food intake 12, 14 and starved animals display increase in hypothalamic NPY mRNA expression. 15 These findings suggest NPY is an important physiological regulator of appetite in the hypothalamus, and is a prime candidate in mediating the central effects of peripheral endocrine factors that regulate feeding behavior. Interestingly, the withdrawal of E 2 in ovariectomized mice results in significantly greater levels of NPY mRNA expression in the arcuate nucleus (ARC). 10, 16 Additional studies found that E 2 treatment resulted in a decrease in NPY release from microdissected hypothalamic sites and paraventricular nucleus cultures. 9 Although E 2 appears to regulate NPY mRNA and release, whether E 2 acts directly on NPY neurons or through afferent neuronal connectivity to influence NPY levels remains yet to be determined. The aim of this study is to determine the secretory events, rapid signal transduction cascades and the E 2 receptor subtype responsible for the anorexigenic action of E 2 on NPY-expressing neurons. To examine the mechanisms by which E 2 regulates NPY within an individual NPY-expressing neuron, we used hypothalamic neuronal cell models derived from both embryonic (e17) and adult (2 month-old) primary cell culture, the mHypoE-42 17 and mHypoA-2/12, 18 respectively. These cell lines have been thoroughly characterized, show neurosecretory properties, express neuron specific markers and have classical neuronal morphology. 17, 19 In this study, we show that 17b-estradiol (E 2 ) directly decreases NPY secretion in both the mHypoE-42 and mHypoA-2/12 neurons. Using pharmacological estrogen receptor (ER)-a and (ER)-b receptor specific agonists/antagonists, we were able to determine that the E 2 -mediated decrease occurred through ER-a in both of the hypothalamic cell lines. Additionally, we detected the colocalization of ER-a and the membrane-associated signaling protein caveolin-1. We found this membrane bound ER-a to be directly involved in the E 2 -mediated decrease in NPY secretion using a combination of E 2 -conjugated BSA (E 2 -BSA) and ER antagonists. Finally, we provide evidence that the phosphatidylinositol-3-kinase PI3K and AMP-activated kinase AMPK pathways have an important role in the estrogen regulation of NPY.
Materials and methods

Cell culture and reagents
The mHypoE-42 and mHypoA-2/12 neurons were grown in monolayer as previously described. 20 Prior to treatments, and used at a concentration of 20 mM. Additional pharmacological agents ER-a selective agonist propyl pyrazole triol (PPT), ER-b-selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), ER-a selective antagonist methyl-piperidino-pyrazole (MPP) and ER-b antagonist R,R-tetrahydrochrysene (R,R)-THC were obtained from Tocris Bioscience. Final treatment concentrations of E 2 and ER-selective agonists were 10 nM, whereas control cells were treated with comparable concentration of vehicle (ethanol, 0.0001% or 14 nM). ER-a selective antagonist MPP and ER-b antagonist (R,R)-THC were applied to neurons for 1 h before E 2 treatment and had a final concentration of 1 mM. E 2 covalently conjugated to bovine serum albumin (E 2 -BSA) was obtained from Sigma Aldrich.
Reverse transcriptase polymerase chain reaction (RT-PCR) Total cellular RNA was isolated from neurons by the guanidium isothyiocyanate phenol-chloroform extraction method. Complementary DNA was made using the Applied Biosystems High Capacity cDNA Reverse Transcriptase Kit (Foster City, CA, USA). For polymerase chain reaction experiments, the primers selected were: ER-aFsense, 5 0 -GAA TTC AAT TCT GAC AAT CGA CGC CAG; anti-sense, 5 0 -GAA TTC GTG CTT CAA CAT TCT CCC TCC (344-bp fragment); ER-bFsense, 5 0 -GAA TTC TAG CCA CCC ACT GCC AAT CAT; anti-sense, 5 0 -GAA TTC CAC ACC TTT CTC TCC TGG ATA (243-bp fragment). All other primers used were previously described. 17 200 ng of cDNA was amplified with 40 polymerase chain reaction cycles for all markers described. RT-PCR products were electrophoresed in 2% agarose gels and stained in an ethidium bromide solution (10 mg ml À1 ethidium bromide in 300 ml 1 Â Tris-acetic acid-EDTA). Gels were visualized under UV light and quantified by densitometry. ). GT1-7 neurons were used as a negative control for secretion assays and did not to secrete detectable levels of NPY (data not shown).
Immunocytochemistry
Statistical analysis
Data was analyzed by statistical analysis of variance followed by a post hoc Tukey's multiple comparison/Bonferroni test or by a Student's t test using Graphpad Prism (Graphpad Software, CA, USA). Experiments were performed on three to twelve separate occasions. Data was considered statistically significant when Po0.05.
Results
Expression of the ER subtypes and other hypothalamic markers in mHypoE-42 and mHypoA-2/12 neurons
The mHypoE-42 and mHypoA-2/12 neurons display neuronal morphology in culture ( Figure 1a) . A partial list of markers ) neurons have the appropriate machinery to respond to estrogen and are suitable models to study the estrogen-mediated regulation of NPY secretion.
Regulation of NPY secretion by E 2 in mHypoE-42 and mHypoA-2/12 neurons Although evidence indicates that E 2 can regulate NPY mRNA and release in vivo, it is not yet known whether this regulation can occur directly at the level of the NPY neuron. The mHypoE-42 and mHypoA-2/12 neurons were exposed to E 2 (10 nM) for 1 h. 10 nM E 2 treatments was used in this study as this was found to be the optimal concentration in our cell models in earlier studies. 19 As a control to ensure accurate NPY measurements, cells were treated with the well-characterized depolarizing agent potassium chloride (60 mM KCl). KCl treatments resulted in a B1.5-fold increase in NPY secretion in both mHypoE-42 and mHypoA-2/12 neurons. Analysis of the results in the embryonic mHypoE-42 neurons indicates that NPY secretion was significantly reduced by E 2 (vehicle, 1.0 ± 0.085; E 2 , 0.83 ± 0.10) (Figure 2a) . Similarly, in the adult hypothalamic cells, mHypoA-2/12, NPY secretion was significantly inhibited by E 2 exposure (vehicle, 1.09±0.0381; E 2 , 0.78±0.052) (Figure 2b ). Figures 3e and f) . Importantly, ER antagonist treatments alone did not significantly change NPY release levels compared with controls. ER agonist/antagonist concentrations used in this study are optimal treatment concentrations established in earlier studies. 20, 21 These results indicate that activation of ER-a mediates the effects of E 2 on the repression of NPY secretion.
E 2 decreases NPY secretion through membrane-bound ER-a
There is some evidence that classical nuclear ER-a can localize to the membrane and lead to the activation of rapid intracellular signaling cascades. 22 We attempted to detect ER-a at the level of the cell membrane by colocalizing ER-a with membrane protein caveolin-1. Using immunocytochemistry with ER-a-and caveolin-1-specific antibodies, we found ER-a could be colocalized at the cell membrane (Figure 4a ). In order to implicate the membrane bound ER-a in the E 2 -mediated decrease in NPY secretion, we used Therefore, it is evident that membrane bound ER-a mediates the effect of E 2 on NPY secretion.
Inhibition of the PI3K and AMPK pathways affect the E 2 -mediated regulation of NPY secretion We next determined whether the regulation of NPY by E 2 is dependent on 'rapid signaling cascades' or membraneassociated signal transduction pathways, MAPK, PI3K and
Estrogen decreases NPY secretion through ER-a SS Dhillon and DD Belsham AMPK, using pharmacological inhibitors specific to these pathways. Neurons were treated with or without E 2 (10 nM) in the presence or absence of pharmacological inhibitors LY294002 (25 mM), UO126 (25 mM) or dorsomorphin (20 mM).
As shown in Figures 5a and b , the E 2 -mediated decrease in NPY was blocked in the presence of the AMPK inhibitor, dorsomorphin dihydrochloride, in both the mHypoE-42 (E 2 , 0.83±0.10; dorsomorphin þ E 2 , 1.05±0.075) and the mHypoA-2/12 (E 2 , 0.78 ± 0.052; dorsomorphin þ E 2 , 1.03 ± 0.030) neurons. Next, we found E 2 co-treatment with the PI3K inhibitor, LY294002, also prevented the E 2 -mediated decrease in NPY secretion in both the embryonic (E 2 , 0.83 ± 0.10; LY294002 þ E 2 , 0.98 ± 0.059) and adult (E 2 , 0.78 ± 0.052; LY294002 þ E 2 , 1.09±0.018) cell lines. In addition, we found that U0126 treatment, a MEK1/2 inhibitor, attenuated the E 2 -mediated decrease in NPY secretion, but this effect was not found to be statistically significant. Importantly, the pharmacological inhibitor treatments alone had no affect on basal NPY secretory levels. Together, our data indicates that activation of the AMPK and PI3K pathways are critical for E 2 to decrease NPY secretion in mHypoE-42 and mHypoA-2/12 neurons.
Discussion
The E 2 is a well-known negative regulator of energy balance, acting peripherally to increase metabolic activity and centrally to reduce food intake. The experiments completed in this study were inspired by earlier work from our lab that showed that E 2 decreased NPY mRNA expression in the mHypoE-38 and mHypoE-42 neurons based through PI3K-and MAPK-dependent mechanisms. 19, 23 Our findings extend these studies by providing the first evidence that acute E 2 exposure can directly regulate NPY secretion. Here, using clonal, immortalized, hypothalamic, NPY-expressing cell lines we investigated the direct regulation of the orexigenic neuropeptide NPY as a central target for E 2 . One hour E 2 exposure in both the embryonic mHypoE-42 and adult mHypoA-2/12 hypothalamic cell lines resulted in a B20% decrease in NPY secretion. We report the E 2 -mediated decrease in NPY occurs exclusively through ER-a, and not ER-b. Further, we found that ER-a can be localized to the cell membrane in our hypothalamic cell lines, and that this membrane-bound receptor was responsible for the reduction in NPY secretion. Finally, through the use of pharmacological inhibitors, we show that the PI3K and AMPK pathways are necessary for the E 2 -mediated decrease in NPY secretion. This study adds to the growing list of evidence that E 2 can regulate NPY levels to modulate feeding behavior and presents the first demonstration that the anorexigenic action of E 2 can act directly through hypothalamic NPY-synthesizing neurons by reducing NPY release. ER-a and ER-b are widely distributed throughout the hypothalamus, with both receptor subtypes present in the arcuate nucleus (ARC) and medial pre-optic area (MPOA). 24, 25 Studies to date have produced conflicting evidence in identifying the ER that is largely responsible for the central anorexigenic role of E 2 . To examine which ER subtype is responsible for the E 2 -mediated reduction in NPY secretion, we treated our neuronal cell lines with ER agonists PPT and DPN, and ER antagonists MPP and (R,R)-THC. We found the ER-a agonist PPT significantly decreased NPY secretion in both the mHypoE-42 and mHypoA-2/12 neurons, whereas DPN failed to invoke a change in NPY secretion. These results were further corroborated by the results of the ER antagonist studies. The ER-a antagonist MPP blocked the E 2 -mediated decrease in NPY secretion, whereas the ER-b antagonist (R,R)-THC, did not. Although we do not implicate ER-b in the regulation of NPY secretion, it does not Estrogen decreases NPY secretion through ER-a SS Dhillon and DD Belsham rule out the possibility that ER-b can regulate other key feeding-related hypothalamic neuropeptides. Recent studies have also indicated that rapid estrogen signaling can involve the G-protein coupled receptor (GPR)-30. 26 Although G-protein coupled receptor (GPR)-30 may contribute to estrogen signaling in the NPY neuron, the estrogen-mediated decrease in NPY secretion observed appears to be independent of G-protein coupled receptor (GPR)-30, as estrogen failed to elicit this response in the presence of the exclusive ER-a antagonist, MPP. In addition, the ER-a agonist, PPT, has not been shown to bind to G-protein coupled receptor (GPR)-30 in vivo or in vitro. Accordingly, our studies indicate E 2 invokes an anorexigenic response by decreasing NPY directly through ER-a in the NPY cell models. Recent studies have shown that estrogen can activate rapid signaling cascades through a subpopulation of classical ERs located at the plasma membrane. 27, 28 In this study,
we were able to colocalize ER-a to the cell membrane invagination scaffold protein caveolin-1. In order to investigate whether membrane bound ER-a has a role in the regulation of NPY secretion, we examined the effect of the cell membrane-impermeable E 2 -BSA in the presence and absence of ER antagonists on NPY release. Here, we showed a similar ER-a-dependent decrease in NPY secretion, indicating E 2 attenuates NPY release through membranebound ER-a. These studies parallel earlier studies that supports ER-a as the anorexigenic target of E 2 in the hypothalamus and present the first line of evidence of the necessary role of membrane bound ER-a in directly regulating NPY levels. To date, E 2 has been reported to activate a number of intracellular signaling cascades through the interaction of various scaffold proteins in a tissue-and cell-specific manner. Interestingly, earlier gene expression studies completed in our lab directly linked the PI3K and MAPK pathways to the E 2 -mediated decrease in NPY gene expression. We therefore used pharmacological inhibitors against these pathways to determine their role in the E 2 -mediated regulation of NPY secretion. We found that the 1 h E 2 -mediated decrease in NPY secretion was significantly attenuated with the PI3K inhibitor, but not the MAPK inhibitor. However, co-treatment of E 2 and the MAPK inhibitor failed to reduce NPY secretion to levels comparable to E 2 treatment alone, suggesting the MAPK pathway may have some role in this effect. We next assessed the role of a novel fuel-sensing enzyme responsible for maintaining metabolic homeostasis, AMPK. AMPK is involved in regulating a number of feedingrelated neuropeptides and is a well-characterized anorexigenic signaling target of leptin in the hypothalamus. 29, 30 We therefore hypothesized that estrogen may also exert its anorexigenic decrease in NPY secretion through the AMPK signaling pathway. To assess the potential role of AMPK in mediating the decrease in NPY secretion by estrogen, we co-treated the mHypoE-42 and mHypoA-2/12 neurons with E 2 and the pharmacological inhibitor, dorsomorphin. We found inhibition of the AMPK pathway was sufficient to also block the E 2 -mediated repression of NPY release. These results support the hypothesis that AMPK is required for the anorexigenic action of E 2 on the NPY neuron. Taken together, these data outline the potential signaling mechanisms that contribute to the reduction in NPY secretion by E 2 .
Considering that the mHypoE-42 and mHypoA-2/12 cell lines are neurons taken from the entire hypothalamus, we can only speculate on the precise nuclei of the hypothalamus from which each clonal cell line originated. To date, a number of feeding-related hypothalamic nuclei have been implicated in the E 2 -mediated decrease in food intake including the paraventricular nucleus, ARC, ventromedial nucleus and the medial pre-optic nucleus . 9, [31] [32] [33] In order to speculate where the mHypoE-42 and mHypoA-2/12 neurons originated from in vivo, we reviewed published data that reported the expression of specific neuropeptides and receptors in these feeding-related hypothalamic nuclei. We found that: (1) in situ hybridization studies implicate ER-b to be the predominant receptor of the paraventricular nucleus and ER-a to be the predominant receptor in the ventromedial nucleus , suggesting the mHypoE-42 and mHypoA-2/12 neurons did not originate from the either of these nuclei; 24, 25 (2) 95% of neurons that co-express AgRP/NPY are localized to the ARC; 11 ( 3) The medial pre-optic area does not express NPY; 32 and (4) ER-a, ER-b and the leptin receptor (Ob-R) are expressed abundantly in the ARC in vivo. Taken together, the ARC is the only feeding-related hypothalamic nuclei known to express ER-a, ER-b, NPY, AgRP and Ob-R. These findings strongly suggest the mHypoE-42 and mHypoA-2/12 neurons originated from the ARC nucleus in vivo as they express these neuroepeptides and receptors (Table 1) . Overall, these observations suggest that the hypothalamic anorexigenic target of E 2 may be NPYsynthesizing neurons that reside in the ARC nucleus. Intact estrogen signaling is essential for the maintenance energy homeostasis. Delineating the hypothalamic targets and signal transduction cascades of E 2 is therefore critical for our understanding of E 2 -related feeding disorders. Our studies show novel rapid signaling mechanisms by which E 2 can directly regulate the release of the most potent orexigenic feeding-related peptide, NPY, in embryonic and Estrogen decreases NPY secretion through ER-a SS Dhillon and DD Belsham adult hypothalamic cell lines. We have found that E 2 can rapidly reduce NPY secretion within 1 h of exposure through neurons likely located in the ARC nucleus. Furthermore, we show that this decrease in NPY secretion is mediated through rapid signaling kinases through ER-a localized at the cell membrane. Specifically, we found E 2 directly reduces NPY secretion through a PI3K-and AMPK-dependent mechanism. These findings provide new information towards our understanding of the central anorexigenic role of E 2 .
